Novel PET scan quickly predicts functional recovery after heart attack

A new approach to PET imaging offers a promising way for physicians to promptly identify patients who are at risk for poor functional recovery after a heart attack, according to new research published in The Journal of Nuclear Medicine.

By visualizing CXCR4--a cellular protein that plays a key role in inflammation--this technique can enable the timely implementation of treatments to mitigate inflammation and prevent heart failure progression.

A heart attack, also known as acute myocardial infarction (AMI), is a major cause of cardiovascular death. According to the Centers for Disease Control and Prevention, more than 800,000 Americans have a heart attack each year. After a heart attack, patients may develop progressive heart failure. Reliable tools to determine which patients will functionally recover and which patients will experience future heart issues, however, are lacking.

We know that AMI triggers an inflammatory response in the heart, which is a determinant of subsequent healing. Our study sought to image this inflammatory response to gain spatial and functional information that could predict outcomes and better inform treatment strategies."

Johanna Diekmann, MD, Senior Physician, Department of Nuclear Medicine, Hannover Medical School

Researchers speculated that CXCR4 upregulation early after AMI would predict left ventricular remodeling in the heart as well as cardiac structural functional outcome. To test this hypothesis, they performed comprehensive multimodal evaluations with CXCR4-targeted PET/CT, myocardial perfusion imaging (MPI), and cardiac MRI on 49 patients within the first week after AMI. A follow-up cardiac MRI was also acquired approximately eight months after AMI in 40 of the patients.

The integrative approach demonstrated that CXCR4 upregulation extends beyond the infarct core, involves the border zone, and correlates with subsequent left ventricular dysfunction. These findings offer mechanistic insight into the link between post-ischemic inflammation and remodeling and underscore the clinical relevance of inflammatory activity after AMI.

"Conventional imaging modalities, including MPI and cardiac MR, predominantly quantify the extent of irreversible tissue damage but do not capture the dynamic inflammatory response that governs healing," noted Diekmann. "By including CXCR4-targeted PET, we can identify patients who exhibit excessive or prolonged inflammation, which may predispose them to adverse remodeling and heart failure. Such information could, in the future, support risk stratification and guide emerging anti-inflammatory or reparative therapies in a precision medicine framework."

"What's more," she continued, "this approach may ultimately facilitate image-guided therapeutic strategies, allowing nuclear medicine to play an active role in monitoring and optimizing interventions that modulate inflammation, repair, and regeneration after cardiac injury."

Source:
Journal reference:

Diekmann, J., et al. (2025). CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction. Journal of Nuclear Medicine. doi.org/10.2967/jnumed.125.270807.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA grants approval to begin Phase I clinical trials of heart tissue regeneration drug AD-NP1